Abstract:Epidemiological studies have convincingly demonstrated that several factors of the metabolic syndrome (MetS) are associated with the risk of Renal Cell Carcinoma (RCC)These factors often occur together and it is therefore challenging to disentangle their individual causal relevance in the etiology of RCC. In order to circumvent this limitation, we have applied a Mendelian randomization (MR) approach whereby genetic markers are evaluated in relation to RCC risk as unconfounded markers of the individual MetS factors. We focused on MetS parameters from which genetic instruments could be identified from large-scale genome-wide association studies (GWAS). The following MetS factors were instrumented using multiple gene-variants: general and central obesity (body mass index (BMI) and waist-to-hip ratio), elevated blood pressure (systolic and diastolic blood pressure), dyslipidemia (high and low density cholesterol, total cholesterol, and triglycerides), hyperglycemia (fasting glucose and glucose levels at 2 hours after glucose intolerance tests), and hyperinsulinemia (fasting insulin). Genetic proxies for these parameters were identified from GIANT, ICBP, GLGC and MAGIC Consortia. Summary statistics on RCC risk for instrumental SNPs of each MetS factor, including OR estimates and standard errors, were available from GWAS coordinated by the International Agency for Research on Cancer, the US National Cancer Institute, the Institute for Cancer Research UK, and the MD Anderson Cancer Center US. Together these studies comprised a total of 12,104 RCC cases and 24,999 controls from European origin that were genotyped using different genotyping platforms. Imputation was conducted on each dataset and only SNPs with an imputation quality higher than 0.6 were considered for the analyses. The causal effect of each MetS parameter on RCC risk was subsequently estimated using the MR likelihood-based approach, assuming a linear relationship between the risk factor and the outcome and a bivariate normal distribution for the genetic association estimates. The MR risk analysis using genetic instruments of the individual MetS factors indicated that elevated BMI (P: 1×10-08) and fasting insulin (P: 7×10-04)increased the risk of RCC, whereas elevated post-load glucose levels were associated with a lower risk (P: 2×10-3). The odds ratio per standard deviation increase were estimated at 1.58 (95% CI: 1.35-1.86) for BMI, 1.77 (95%CI: 1.27-2.46) for fasting insulin, and 0.62 (95%CI: 0.46-0.83) for post-load glucose. No associations were seen for genetic instruments of blood pressure or lipids. These results provide a clear support for a causal role of obesity in RCC etiology, and suggest that factors related to hyperglycemia and/or hyperinsulinemia may be involved in the causal pathway. This study may guide future efforts aiming to clarify the biological mechanisms whereby the metabolic syndrome influences RCC pathogenesis. Citation Format: Robert Carreras-Torres, Mattias Johansson, Ghislaine Scelo, Philip Haycock, Mark Purdue, Xifeng Wu, Richard Houlston, Stephen Chanock, Paul Brennan. Identifying causal risk factors of metabolic syndrome for renal cell carcinoma. A Mendelian randomization approach. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4349.

Abstract 673: Obesity, Weight Gain, Physical Activity and Polymorphism in Mtor Pathway and Risk of Renal Cell Carcinoma

Energy Balance, Polymorphisms in the Mtor Pathway, and Renal Cell Carcinoma Risk

Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer

Association of PI3K/AKT/mTOR Pathway Genetic Variants with Type 2 Diabetes Mellitus in Chinese.

The Influence of Obesity-Related Factors in the Etiology of Renal Cell Carcinoma—a Mendelian Randomization Study

Abstract 1262: Established Genetic Variants and Dietary Patterns Jointly Impact Risk of Renal Cell Carcinoma in Non-Hispanic Whites

Abstract 4349: Identifying Causal Risk Factors of Metabolic Syndrome for Renal Cell Carcinoma. A Mendelian Randomization Approach

Abstract 2634: Prognostic Value of Obesity-Related Genes Methylation in Localized Renal Cell Carcinoma Patients

A Functional Variant in the MTOR Promoter Modulates Its Expression and is Associated with Renal Cell Cancer Risk

Polymorphisms in the Mtor Gene and Risk of Sporadic Prostate Cancer in an Eastern Chinese Population

Genetic Variants in Mtor-Pathway-related Genes Contribute to Osteoarthritis Susceptibility.

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

Germline Genetic Variants in Somatically Significantly Mutated Genes in Tumors Are Associated with Renal Cell Carcinoma Risk and Outcome

Genetic Variations of Mtorc1 Genes and Risk of Gastric Cancer in an Eastern Chinese Population.

Impacts of the Mtor Gene Polymorphisms Rs2536 and Rs2295080 on Breast Cancer Risk in the Chinese Population

Abstract A23: Gene Set Enrichment Analysis of Renal Cell Carcinoma Genome-Wide Association Data Identifies the JAK-STAT Pathway Mediating Susceptibility

Polymorphisms in Mtorc1 Genes Modulate Risk of Esophageal Squamous Cell Carcinoma in Eastern Chinese Populations.

Association of Breast Cancer Risk and the Mtor Pathway in Women of African Ancestry in 'the Root' Consortium.

Case-control Analysis of Nucleotide Excision Repair Pathway and the Risk of Renal Cell Carcinoma.

Association Between Mitogen-Activated Protein Kinase Kinase Kinase 1 Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis of 20 Case-Control Studies

Association of Single Nucleotide Polymorphisms in Agt, Vegf, and Apoe Genes with Clinical Outcome of Target Therapy in Advanced Renal Cell Carcinoma